Health Care [ 4/12 ] | Biotechnology [ 21/75 ]
NASDAQ | Common Stock
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform.
Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.
The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 28, 24 | -6.06 | - |
| May 29, 24 | -22.36 | - |
| Mar 2, 22 | -9.37 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -1.99 M Decreased by -300.97% | - - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -1.99 M Decreased by -79.97% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -3.32 M Decreased by N/A% | Decreased by N/A% - |
| Sep 30, 23 | N/A Decreased by N/A% | -3.13 M Decreased by -206.98% | - - |
| Jun 30, 23 | 0.00 Decreased by N/A% | 988.49 K Increased by +N/A% | Increased by +N/A% - |
| Mar 31, 23 | 0.00 Decreased by -100.00% | -1.10 M Increased by +71.70% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | N/A Decreased by -100.00% | N/A Increased by +100.00% | - - |
| Sep 30, 22 | N/A Decreased by -100.00% | -1.02 M Increased by +85.49% | - - |